- /
- Supported exchanges /
- NASDAQ /
- ROIV.NASDAQ
Roivant Sciences Ltd (ROIV NASDAQ) stock market data APIs
Roivant Sciences Ltd Financial Data Overview
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Roivant Sciences Ltd data using free add-ons & libraries
Get Roivant Sciences Ltd Fundamental Data
Roivant Sciences Ltd Fundamental data includes:
- Net Revenue: 129 M
- EBITDA: -1 199 662 976
- Earnings Per Share: 5
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-12
- EPS/Forecast: -0.26
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Roivant Sciences Ltd News
Is Roivant Sciences Ltd. (NASDAQ:ROIV) The Best NASDAQ Stock Under $50 To Buy?
We recently made a list of the 10 Best NASDAQ Stocks Under $50 to Buy. In this piece, we will look at where Roivant Sciences Ltd. (NASDAQ:ROIV) ranks among the best NASDAQ stocks under $50 to buy. ...
Is Roivant Sciences Ltd. (ROIV) the Best Guru Stock To Buy Now?
We recently compiled a list of the 10 Best Guru Stocks To Buy Now. In this article, we will have a look at where Roivant Sciences Ltd. (NASDAQ:ROIV) ranks among the best guru stocks to buy now. Due t...
Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
Roivant Sciences VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an additional indication to treat atopic dermat...
Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer
Roivant Sciences Unveils New 'Vant' Subsidiary For In-Licensed Pulmonary Hypertension Drug From Bayer Tuesday, Roivant Sciences Ltd. (NASDAQ:ROIV) created Pulmovant to in-license from Bayer AG (OTC:...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.